FDA approves Illumina cancer biomarker test with two companion ...

Illumina announced FDA approval of its cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies.

Illumina announced FDA approval of its cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies.

FDA approves Illumina's tumor biomarker test as a pan-cancer ...

FDA approves Illumina's tumor biomarker test as a pan-cancer companion diagnostic ... Illumina has secured an FDA approval to bring its pan-cancer ...

Illumina wins FDA approval for companion diagnostic cancer test

The test uses Illumina's Nextseq 550Dx sequencing instrument to detect variants in 517 genes using nucleic acids extracted from solid tumor ...

FDA Approves Illumina Cancer Biomarker Test

FDA Approves Illumina Cancer Biomarker Test ... two companion diagnostics – aimed to match patients with targeted therapies or clinical trials ...

FDA Approves Cancer Biomarker Test, Companion Diagnostic ...

This targeted sequencing panel interrogates over 500 genes to profile a patient's solid tumor, helping to increase the likelihood of identifying ...

FDA approves Illumina cancer biomarker test plus two CDxs

... Oncology Comprehensive test and its first two companion diagnostic indications. This single test interrogates more than 500 genes to profile ...

FDA approves next-generation cancer biomarker test and ... - ADLM

The company says the test is the first FDA-approved, distributable comprehensive genomic profiling IVD kit with pancancer companion diagnostic ...

FDA Approves Illumina Cancer Test with Two Companion ...

This advanced test, which profiles over 500 genes, is designed to support precision oncology by evaluating solid tumors and identifying critical biomarkers.

FDA grants approval to Illumina's cancer biomarker test with two ...

Illumina has secured approval from the US Food and Drug Administration (FDA) for its TruSight Oncology (TSO) Comprehensive test and its two companion ...

Illumina Gets FDA Approval for Cancer Biomarker Test - MarketWatch

Illumina received Food and Drug Administration approval for its TruSight Oncology Comprehensive biomarker test for cancer and its two companion diagnostic uses.

FDA Approves Cancer Biomarker Test with Two Companion ...

The FDA approved Illumina's oncology comprehensive test as an IVD tool, along with its first two CDx indications for cancer patients.

FDA Approves TruSight Oncology Comprehensive Assay As Pan ...

The TruSight Oncology Comprehensive Assay has been approved by the FDA with companion diagnostic claims in NSCLC and NTRK-positive solid ...

TruSight Oncology Test Receives FDA Approval for NTRK and RET ...

The TruSight Oncology Comprehensive test has been approved by the FDA as a companion diagnostic for NTRK-fusion positive solid tumors and ...

FDA approves Illumina cancer biomarker test plus two CDxs

Oncology Comprehensive test and its first two companion diagnostic indications. This single test interrogates more than 500 genes to profile ...

FDA gives approval to Illumina's cancer biomarker test with two CDx ...

... Food and Drug Administration (FDA) for its TruSight Oncology (TSO) Comprehensive test and its two companion diagnostics indications.

FDA Approves Biomarker Test for Use in NSCLC, Other Solid Tumors

The US Food and Drug Administration (FDA) has approved Illumina's TruSight Oncology Comprehensive test for use as a companion diagnostic to identify cancer ...

Illumina's Cancer Biomarker Test With Two Companion Diagnostics ...

(RTTNews) - Illumina, Inc. (ILMN), Tuesday announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight ...

FDA approves Illumina cancer biomarker test - Pharma Manufacturing

The FDA has approved Illumina's TruSight Oncology (TSO) Comprehensive test, the first distributable comprehensive genomic profiling in vitro diagnostic (IVD) ...

Illumina's IVD Biomarker Test Becomes the First FDA-approved Pan ...

Illumina's TSO Comprehensive is the first FDA-approved comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims.